BBAGF
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q4 | 8.62 | $475M | — |
| 2025 Q2 | -1.83 | -$94M | -$60M |
| 2025 Q1 | -4.40 | $108,000 | $289M |
| 2024 Q4 | 1.09 | $67M | $157M |
| 2024 Q3 | -2.84 | -$148M | $49M |
| 2024 Q2 | -1.60 | -$78M | $27M |
| 2024 Q1 | 4.71 | $271M | $71M |
| 2023 Q4 | 1.99 | $111M | -$928,000 |